Recent advances in scaffold-based KRASG12C inhibitors: SAR and biological evaluation insights.
Over the past decade, targeting Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations has shifted from being considered an undruggable target to becoming a realistic therapeutic strategy with the development of KRASG12C inhibitors. This mutation replaces glycine with cysteine at codon 12, thereby reducing the GTP...